Jacobs Levy Equity Management, Inc Metacrine, Inc. Transaction History

Jacobs Levy Equity Management, Inc

  • $21.8 Billion
  • Q1 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$2.61 - $3.84 $37,281 - $54,850
-14,284 Closed
0 $0
Q2 2021

Aug 16, 2021
SELL
$3.37 - $5.73 $3,612 - $6,142
-1,072 Reduced 6.98%
14,284 $54,000
Q1 2021

May 17, 2021
BUY
$6.2 - $11.0 $95,207 - $168,916
15,356 New
15,356 $95,000

Others Institutions Holding MTCR

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About Metacrine, Inc.

MTCR Quotes by TradingView
  • Ticker MTCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,569,500
  • Description
  • Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
More about MTCR
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email